Side 1 fra 17 resultater
BACKGROUND OF THE INVENTION
Prostate cancer (PC) is the most common tumor in men in western countries, and the second cause of cancer-related death among them. Almost 80% of cases are diagnosed as localized disease, and radiation or surgery can be curative. However, despite current treatment
BACKGROUND OF THE INVENTION
Prostate cancer (PC) is the most common tumor in men in western countries, and the second cause of cancer-related death among them. Almost 80% of cases are diagnosed as localized disease, and radiation or surgery can be curative. However, despite current treatment
BACKGROUND OF THE INVENTION
Obesity, defined as excess adiposity for a given body size, results from a chronic imbalance between energy intake and energy expenditure. Body mass index (BMI, kg/m.sup.2) is an accepted clinical estimate of being overweight (BMI 25 to 30) and of obesity (BMI>30). A
TECHNICAL FIELD
The present invention relates to compounds with biological activity and pharmaceutical and cosmetic formulations thereof, their derivatives and methods of use, more specifically the present invention includes compounds with at least one (substituted phenyl)-propenal moiety and their
TECHNICAL FIELD
The present invention relates to compounds with biological activity and pharmaceutical and cosmetic formulations thereof, their derivatives and methods of use, more specifically the present invention includes compounds with at least one (substituted phenyl)-propenal moiety and their
TECHNICAL FIELD
The present invention relates to compounds with biological activity and pharmaceutical and cosmetic formulations thereof, their derivatives and methods of use, more specifically the present invention includes compounds with at least one (substituted phenyl)-propenal moiety and their
FIELD OF THE INVENTION
The present invention relates to novel compounds which are useful as the agents for prevention or treatment of diseases associated with histone deacetylase (HDAC), in particular, tumor or cell proliferative diseases. They also can be used as the agents for enhancing the
BACKGROUND
Technical Field
The present invention relates to compounds with biological activity and pharmaceutical and cosmetic formulations thereof, their derivatives and methods of use, more specifically the present invention includes compounds with at least one (substituted phenyl)-propenal moiety
The present invention relates to xanthine derivatives having at least one alkylphosphonate or alkylphosphine oxide group in the 1- or 7-position. These compounds are suitable for the treatment of muscular atrophy, muscular dystrophy, cachexia, sepsis, septic shock, endotoxic shock, systemic
TECHNICAL FIELD
This invention relates to enzyme inhibitors, and more particularly to histone deacetylase inhibitors.
BACKGROUND
DNA in the nucleus of the cell exists as a hierarchy of compacted chromatin structures. The basic repeating unit in chromatin is the nucleosome. The nucleosome consists of
TECHNICAL FIELD
This invention relates to trihalomethylcarbonyl compounds, and more particularly to trihalomethylcarbonyl compounds that are histone deacetylase inhibitors.
BACKGROUND
DNA in the nucleus of the cell exists as a hierarchy of compacted chromatin structures. The basic repeating unit in
TECHNICAL FIELD
This invention relates to alpha-ketoepoxide compounds, and more particularly to alpha-ketoepoxide compounds that are histone deacetylase inhibitors.
BACKGROUND
DNA in the nucleus of the cell exists as a hierarchy of compacted chromatin structures. The basic repeating unit in
TECHNICAL FIELD
This invention relates to alpha-ketoepoxide compounds, and more particularly to alpha-ketoepoxide compounds that are histone deacetylase inhibitors.
BACKGROUND
DNA in the nucleus of the cell exists as a hierarchy of compacted chromatin structures. The basic repeating unit in
TECHNICAL FIELD
This invention relates to alpha-chalcogenmethylcarbonyl compounds, and more particularly to alpha-chalcogenmethylcarbonyl compounds that are histone deacetylase inhibitors.
BACKGROUND
DNA in the nucleus of the cell exists as a hierarchy of compacted chromatin structures. The basic
TECHNICAL FIELD
This invention relates to alpha-ketoepoxide compounds, and more particularly to alpha-ketoepoxide compounds that are histone deacetylase inhibitors.
BACKGROUND
DNA in the nucleus of the cell exists as a hierarchy of compacted chromatin structures. The basic repeating unit in